BMJ Open Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan

Chang-Hung Tsai,^{1,2} Pei-Tseng Kung,^{3,4} Wei-Yin Kuo,⁵ Wen-Chen Tsai ⁵

To cite: Tsai C-H, Kung P-T, Kuo W-Y, *et al.* Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan. *BMJ Open* 2020;**10**:e034351. doi:10.1136/bmjopen-2019-034351

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2019-034351>).

P-TK and W-CT contributed equally.

Received 16 September 2019
Revised 07 March 2020
Accepted 12 March 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Wen-Chen Tsai;
wtsai@mail.cmu.edu.tw

ABSTRACT

Objectives This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

Study design This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42 962 patients with newly diagnosed NSCLC.

Methods We identified 42 962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

Results We included 42 962 patients (15 799 men and 27 163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted HRs ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment ≤7 days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II and stage III.

Conclusions There is a major association between time to treat and mortality of patients with NSCLC, especially in stages I and II. We suggest that efforts should be made to minimise the interval from diagnosis to treatment while further study is ongoing to determine causation.

INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialised countries.¹ In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,² becoming a worldwide public health issue.³ Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC), of which the latter accounts for 80% of all lung cancer cases.⁴ Despite recent improvements in treatment, the prognosis for patients with lung cancer is still poor. Regardless of whether a patient has NSCLC or small cell lung cancer,

Strengths and limitations of this study

- It consisted of nationwide patients with non-small cell lung cancer.
- We collected nationwide data from 42 962 patients with non-small cell lung cancer, which is the largest nationwide study to date.
- There were very few studies investigating treatment delay effects on the reduction of survival rate of patients with lung cancer.
- Our lung cancer stages (stages I, II, III and IV) were based on pathological confirmation.
- Information on patients' quantitative lung function and need for provocative cardiac testing are not available and may be significant factors determining the time to treat interval.

the 5-year survival rate is only 17.4%.^{2 5–7} Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.⁸ There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.⁴ Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of patients with lung cancer, no definitive conclusion has been reached.⁴ An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) programme. Under this system, lung cancer is classified as a catastrophic illness and is exempt from treatment-related fees, thereby that patients are not affected by economic factor. According to 2016 statistics from the Taiwan Ministry of Health and Welfare, cancer has consistently been the top cause of death. Among various types of

cancer, lung cancer ranks first in the cause of death, with a mortality rate of 39.9 per 100 000 people. Therefore, it is important for public health providers to improve lung cancer prognoses and increase survival rates. The Taiwan Cancer Registry, a population-based cancer registry, was founded in 1979. The registry is organised by the Ministry of Health and Welfare. The Taiwan Cancer Registry Database records data of all types of cancer diagnosed and treatments in patients in Taiwan. The completeness (97%) and data quality of the Cancer Registry Database has achieved at an excellent level.⁹ The accuracy of National Health Insurance Research Database (NHIRD) has been validated in previous studies.¹⁰ This study aims to use national large-scale statistical data to investigate whether the interval between lung cancer diagnosis and treatment affects survival rate; concurrently, we also aim to examine the impact of other relevant factors on survival. This will provide a reference for future treatment for patients with lung cancer of improving their survival.

METHODS

Data sources and participants

We included 55 014 newly diagnosed patients with NSCLC from 2004 to 2010. The newly diagnosed patients with NSCLC were defined as International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) with C339 to C349 without any cancers before. Then we excluded those lung cancer patients with unknown stage for 3993 patients. We also excluded patients with lung cancer in situ (70 patients), with multiple cancer (1298 patients), palliative treatment at the beginning (1934 patients), mortality before lung cancer diagnosed (64 patients), personal characteristics data missing (109 patients) and hospital data missing (4584 patients). In our study, patients with multiple cancers may affect survival due to other cancer effect. In Taiwan, palliative treatment is coded as special code in NHIRD. NSCLC patients with palliative treatment at beginning may be due to patients refusing further treatment or not receiving aggressive treatment. We excluded them for informal treatment. Otherwise, we also excluded those patients with data missing for accuracy. Finally, we had 42 962 people.

The data for this study were obtained from the Taiwan Cancer Registry, which was used to acquire study participants. We also linked this data to the National Health Insurance Database and the Cause of Death File from 2002 to 2012 that was provided by the Ministry of Health and Welfare. The accuracy of Taiwan Cancer Registry and NHIRD has achieved at an excellent level.

Patient and public involvement

No patients were involved in the planning, conception and design of this study, as this study was based on the NHIRD, published by the Ministry of Health and Welfare, Taiwan.

Variable descriptions

In this study, with regards to the variables used, the general characteristics of patients with lung cancer

included sex and age. Age was defined as the age at which the patient had a confirmatory diagnosis by pathology. The financial status of the patient was based on their monthly salary. The degree of urbanisation at the patient's place of residence was used to represent environmental factors. The level of urbanisation was based on seven levels of classification from highly urbanised developed cities (level 1) to remote areas (level 7). The health status of the patient included data on whether the patient had other catastrophic illnesses besides cancer, their Charlson Comorbidity Index (CCI) and the stage of NSCLC. The definition of catastrophic illness was based on the 30 types of catastrophic illnesses or injuries as defined by the National Health Insurance Administration, which include stroke, chronic kidney failure, systemic lupus erythematosus, type I diabetes and severe mental illness. The degree of comorbidity was classified into three levels based on the CCI.¹¹ Tumour staging was based on the guidelines of the American Joint Committee on Cancer (6th edition for tumours diagnosed from 2004 to 2009, 7th edition for tumours diagnosed in 2010), which includes stages I, II, III and IV. Hospital attributes include the level of hospital (medical centres, regional hospitals, district hospitals and others), hospital ownership (public or private institutions) and the volume of hospital services (low, medium and high) in treatment of patients with NSCLC. The volume of hospital services was divided into low, medium and high on the basis of quartiles: service volumes of <25%, 25%–75% and >75% were defined as low, medium and high, respectively. Patients were considered to be enrolled in multidisciplinary team (MDT) care if they received MDT treatment after pathological diagnosis of NSCLC; the definition of MDT is based on patients who were declared MDT treatment fees in the NHI database (47 079B). The interval between diagnosis of NSCLC and treatment initiation was defined as the period between pathological sectioning and diagnosis of NSCLC after biopsy to the time when the patient underwent their first treatment (including surgery, radiotherapy or chemotherapy). The operating definition of relevant treatments is based on the relevant treatment code that was declared in the NHI database, which was checked against the treatment registration information in the Taiwan Cancer Information Database.

Main outcome measurements

The main outcome examined in this study was the survival rate of patients with lung cancer. Confirmation of death was based on patient data from the NHI database and this was compared with the Taiwan Cause of Death archives for confirmation.

Statistical analysis

We employed descriptive statistics to show general characteristics, financial status, environmental factors, health status of patients, hospital attributes, enrolment in MDT and the distribution status of the interval from diagnosis confirmation to treatment initiation in patients with lung

cancer who had a confirmatory diagnosis by pathology from 2004 to 2010. Following this, bivariate analysis was performed using the log-rank test to investigate whether there were significant differences between survival status by the end of 2012 and the interval from diagnosis to treatment initiation. We then used univariate Cox proportional hazards regression to analyse relevant prognostic factors that affect the survival of patients with lung cancer. The adjusted Cox proportional hazards model was used to investigate the relative risk of survival of lung cancer patients with different cancer stages with different intervals from diagnosis confirmation to treatment initiation, after controlling for related variables. Independent variables included patient characteristics, financial status, environmental factors, health status, hospital attributes, enrolment in MDT and grouping of time to treatment initiation. The dependent variable was survival. Lastly, after controlling for relevant variables, the adjusted Cox proportional hazards model was used to generate survival curves for patients with lung cancer of various stages and with different interval periods.

All statistical analyses were performed using SAS software, V.9.2. A p value <0.05 was regarded as statistically significant, and all tests were two sided.

RESULTS

Descriptive statistics of lung cancer patient characteristics for different treatment intervals

In all patients with lung cancer, the mean 5-year survival rate was 17.61%. As the interval from diagnosis to treatment initiation increased, the 5-year survival rate decreased from 26.12% to 6.02% (table 1). We also included time to treatment with 0 day (TTT=0) cases in the <7 days group in our study. There were 7363 cases with TTT=0 accounting for 17.14% of all patients in our study. We had 3258 females accounting for 44.25% in this subgroup. The age of diagnosed in most patients was from 65 to 74 years old accounting for 28.28% with mean age of 64.67 years old. The treatment of most patients with TTT=0 was surgery combining with radiotherapy and chemotherapy. The 5-year survival rate was 34.9% in this group with TTT=0.

Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 9.07% due to delayed treatment (patients with intervals >7 days). In stage II patients, if patients started treatment earlier (interval ≤7 days), their 5-year survival rate increased by 9.01%. Early treatment (interval ≤7 days) was found to have a smaller effect on 5-year survival rate in stage III and stage IV patients, with an increase in 5-year survival rate of 1.91% and 0.49% (table 2).

The effect of different treatment intervals on mortality risk in patients with lung cancer

Table 3 shows that when the group with interval from cancer diagnosis to treatment ≤7 days was used as a

reference, the adjusted HR for mortality in other groups (8–14 days, 15–60 days and ≥61 days) was significantly increased with increasing interval time (HR 1.04–1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR 2.06–5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR 0.91, 95% CI 0.88 to 0.94).

The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in patients with stage I lung cancer, with patients with intervals of ≤7 days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR 1.45–2.41). This was also true for stage II (HR 1.21–1.58) and the intervals more than 60 days of patients with stage III lung cancer (HR 1.13, 95% CI 1.06 to 1.21). In stage IV patients, using patients with an interval ≤7 days as a reference group, the relative risk of death was without significantly difference. Figure 1 shows adjusted survival curve in lung cancer patients with different cancer stages.

DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.^{12 13} The delays between diagnosis and treatment can be categorised into three stages, namely, patient delay, diagnosis delay and treatment delay.² Of all studies that investigated treatment delays in patients with lung cancer, the study with the largest number of patients included 54338 patients but was limited to patients with non-metastatic lung cancer.¹² In addition, the study only focused on patients who underwent surgical excision and did not analyse the treatment delay status and associated factors for all patients with lung cancer. Another study collected data from 28732 patients to investigate whether treatment delay affects survival rate.¹⁴ The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localised disease and reduced survival for those with distant disease but did not have significant effect on patients with regional disease.¹⁴ However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment delay periods affect survival rate for different cancer stages as they only classified cancers as localised, regional or distant. To the best of our knowledge, the current study is the first large-scale nationwide

Table 1 Bivariate analysis of lung cancer patient characteristics for different treatment intervals

Variables	Interval from cancer diagnosis to treatment										P value
	Total		≤7 days		8~14 days		15~60 days		≥61 days		
	N	%	N	%	N	%	N	%	N	%	
Total number	42 962	100	15 769	36.7	9296	21.64	12 510	29.12	5387	12.54	–
Five-year survival rate	42 962	17.61	15 769	26.12	9296	15.96	12 510	12.99	5387	6.02	<0.001
Gender											
Female	15 799	36.77	6154	38.95	3235	20.48	4419	27.97	1991	12.6	
Male	27 163	63.23	9615	35.4	6061	22.31	8091	29.79	3396	12.5	
Age											
≤44	2106	4.9	889	42.21	455	21.6	568	26.97	194	9.21	
45~54	5686	13.23	2375	41.77	1263	22.21	1549	27.24	499	8.78	
55~64	9155	21.31	3634	39.69	2033	22.21	2658	29.03	830	9.07	
65~74	12 659	29.47	4548	35.93	2801	22.13	3819	30.17	1491	11.78	
≥75	13 356	31.09	4323	32.37	2744	20.55	3916	29.32	2373	17.77	
Mean age (m, SD)	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
Monthly salary											<0.001
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤17 280	1475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17 281~22 800	22 935	53.38	8074	35.2	5079	22.15	6751	29.44	3031	13.22	
22 801~28 800	8069	18.78	2961	36.7	1690	20.94	2376	29.45	1042	12.91	
28 801~36 300	2676	6.23	1011	37.78	588	21.97	782	29.22	295	11.02	
36 301~45 800	3280	7.63	1333	40.64	689	21.01	923	28.14	335	10.21	
≥45 801	4066	9.46	1711	42.08	838	20.61	1077	26.49	440	10.82	
Urbanisation											0.186
Level 1	11 759	27.37	4335	36.87	2494	21.21	3404	28.95	1526	12.98	
Level 2	12 117	28.2	4506	37.19	2615	21.58	3527	29.11	1469	12.12	
Level 3	6523	15.18	2334	35.78	1424	21.83	1946	29.83	819	12.56	
Level 4	6795	15.82	2518	37.06	1506	22.16	1974	29.05	797	11.73	
Level 5	1524	3.55	523	34.32	338	22.18	439	28.81	224	14.7	
Level 6	2217	5.16	807	36.4	490	22.1	627	28.28	293	13.22	
Level 7	2027	4.72	746	36.8	429	21.16	593	29.26	259	12.78	
CCI score											<0.001
≤3	20 388	47.46	7475	36.66	4576	22.44	6186	30.34	2151	10.55	
4~6	7587	17.66	2761	36.39	1646	21.7	2218	29.23	962	12.68	
≥7	14 987	34.88	5533	36.92	3074	20.51	4106	27.4	2274	15.17	
Other catastrophic illness											<0.001
No	41 474	96.54	15 300	36.89	8984	21.66	12 076	29.12	5114	12.33	
Yes	1488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
Cancer stage											<0.001
Stage I	5681	13.22	3226	56.79	910	16.02	1269	22.34	276	4.86	
Stage II	1526	3.55	589	38.6	338	22.15	462	30.28	137	8.98	
Stage III	11 696	27.22	4030	34.46	2843	24.31	3500	29.92	1323	11.31	
Stage IV	24 059	56	7924	32.94	5205	21.63	7279	30.25	3651	15.18	
MDT care											<0.001
No	37 716	87.79	13 669	36.24	8012	21.24	10 974	29.1	5061	13.42	
Yes	5246	12.21	2100	40.03	1284	24.48	1536	29.28	326	6.21	

Continued

Table 1 Continued

Variables	Interval from cancer diagnosis to treatment										P value	
	Total		≤7 days		8~14 days		15~60 days		≥61 days			
	N	%	N	%	N	%	N	%	N	%		
Hospital level												<0.001
Medical centres	29228	68.03	11075	37.89	6452	22.07	8427	28.83	3274	11.2		
Regional hospitals	12601	29.33	4395	34.88	2655	21.07	3787	30.05	1764	14		
District hospitals	1014	2.36	261	25.74	178	17.55	279	27.51	296	29.19		
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54		
Hospital ownership												<0.001
Public	16770	39.03	6619	39.47	3776	22.52	4558	27.18	1817	10.83		
Private	26192	60.97	9150	34.93	5520	21.08	7952	30.36	3570	13.63		
Hospital services volume												<0.001
Low	10807	25.15	3905	36.13	2177	20.14	2935	27.16	1790	16.56		
Middle	21043	48.98	7519	35.73	4652	22.11	6486	30.82	2386	11.34		
High	11112	25.86	4345	39.1	2467	22.2	3089	27.8	1211	10.9		

*Log-rank test.

CCI, Charlson Comorbidity Index; MDT, multidisciplinary team.

study that examines whether treatment delay in NSCLC affects patient survival rate. In addition, we also investigated the correlation between lung cancer treatment delay and survival rate for different cancer stages (stages I, II, III and IV).

Previous studies have observed that if patients are older, have more comorbidities or have stage I cancer, they are more likely to delay treatment (interval from diagnosis to treatment >30 days).¹² Similar findings were observed in our study: for patients aged ≥ 55 years, the greater the age, the greater the proportion with treatment delay (interval ≥ 61 days) (table 1). Patients with high CCI scores also demonstrated significantly increased proportions in treatment delay (interval ≥ 61 days) (table 1). CCI is a general score to evaluate patients' comorbidity and does not focus on patients with lung cancer. The lung function testing such as forced expiratory volume in 1 s (FEV_1) and diffusing capacity of the lung for carbon monoxide (DLCO) is more accurate for evaluating their severity but is not available in our study. It is a fact that patients with

poorer lung function require additional testing to determine candidacy for surgery. This testing, including 6 min walk test, quantitative perfusion scans, cardiopulmonary exercise testing and consultation with pulmonary medicine takes time and is not available in our study. However, during analysis of the correlation between treatment delay and lung cancer stage, we found that the proportion of stage I patients with treatment delay was significantly lower than patients with other stages of lung cancer. A previous study has observed that in patients with NSCLC, treatment delay is not associated with cancer stage.^{15–20} In contrast, treatment delay had more serious effects in stage III and IV patients.²¹ However, in our study, we found that the proportion of stage I patients with treatment delay (interval from diagnosis to treatment ≥ 61 days) was significantly lower (4.86%, $p<0.001$) when compared with patients at other stages.

Previous studies have mentioned that in patients with NSCLC, our understanding of the effects of diagnosis and treatment delay on the prognosis of patients is

Table 2 Five-year survival rate of patients for different treatment intervals

Variables	Stage I		Stage II		Stage III		Stage IV		P value *
	N	%	N	%	N	%	N	%	
Total number	5681	61.61	1526	34.41	11696	12.95	24059	5.11	
Interval from cancer diagnosis to treatment									<0.001
≤ 7 days	3226	70.68	589	43.42	4030	14.86	7924	5.60	
8~14 days	910	60.58	338	33.74	2843	12.11	5205	4.58	
15~60 days	1269	49.07	462	29.81	3500	13.81	7279	5.43	
≥ 61 days	276	21.10	137	14.56	1323	6.83	3651	4.12	

*Log-rank test.

Table 3 Relative risk of death in patients for different treatment intervals

Variables	Unadjusted		Adjusted		
	HR	P value	HR	95% CI	P value*
Interval from cancer diagnosis to treatment					
≤7 days (ref.)					
8~14 days	1.26	<0.001	1.04	1.01 to 1.07	0.004
15~60 days	1.30	<0.001	1.06	1.04 to 1.09	<0.001
≥61 days	1.66	<0.001	1.08	1.04 to 1.11	<0.001
Gender					
Female (ref.)					
Male	1.54	<0.001	1.50	1.47 to 1.53	<0.001
Age (years)					
≤44 (ref.)					
45~54	0.97	0.357	0.97	0.92 to 1.03	0.351
55~64	1.02	0.478	1.03	0.97 to 1.09	0.331
65~74	1.63	<0.001	1.27	1.21 to 1.34	<0.001
≥75	1.93	<0.001	1.79	1.69 to 1.88	<0.001
Monthly salary					
Low income (ref.)					
≤17 280	0.72	<0.001	0.89	0.80 to 1.00	0.049
17 281~22 800	0.81	<0.001	0.86	0.78 to 0.95	0.002
22 801~28 800	0.74	<0.001	0.83	0.75 to 0.91	<0.001
28 801~36 300	0.60	<0.001	0.79	0.71 to 0.87	<0.001
36 301~45 800	0.59	<0.001	0.78	0.70 to 0.87	<0.001
≥45 801	0.56	<0.001	0.73	0.66 to 0.81	<0.001
Urbanisation level					
Level 1 (ref.)					
Level 2	1.07	<0.001	0.99	0.96 to 1.02	0.523
Level 3	1.20	<0.001	1.04	1.00 to 1.07	0.036
Level 4	1.21	<0.001	1.01	0.98 to 1.05	0.596
Level 5	1.33	<0.001	1.01	0.95 to 1.08	0.671
Level 6	1.39	<0.001	1.09	1.04 to 1.15	0.001
Level 7	1.25	<0.001	1.02	0.96 to 1.07	0.570
CCI score					
≤3 (ref.)					
4~6	1.35	<0.001	1.18	1.14 to 1.21	<0.001
≥7	1.80	<0.001	1.28	1.25 to 1.31	<0.001
Other catastrophic illness					
No (ref.)					
Yes	1.25	<0.001	1.26	1.19 to 1.33	<0.001
Cancer stage					
Stage I (ref.)					
Stage II	2.29	<0.001	2.06	1.91 to 2.23	<0.001
Stage III	4.48	<0.001	3.94	3.75 to 4.13	<0.001
Stage IV	6.51	<0.001	5.89	5.62 to 6.17	<0.001
MDT care					
No (ref.)					

Continued

Table 3 Continued

Variables	Unadjusted		Adjusted		
	HR	P value	HR	95% CI	P value*
Yes	0.95	0.001	0.91	0.88 to 0.94	<0.001
Hospital level					
Medical centres (ref.)					
Regional hospitals	1.28	<0.001	0.99	0.96 to 1.02	0.347
District hospitals	2.06	<0.001	1.25	1.17 to 1.34	<0.001
Others	1.17	0.137	0.90	0.73 to 1.10	0.286
Hospital ownership					
Public (ref.)					
Private	1.27	<0.001	1.13	1.10 to 1.16	<0.001
Hospital services volume					
Low (ref.)					
Middle	0.72	<0.001	0.83	0.81 to 0.85	<0.001
High	0.59	<0.001	0.71	0.68 to 0.74	<0.001

*Cox proportional hazards regression.

CCI, Charlson Comorbidity Index; MDT, multidisciplinary team.

limited, although an increasing number of recent studies are emphasising the importance of this topic.⁴ Some studies have found that in patients with a symptom-to-treatment interval (STI) of >60 days, the survival rate was significantly higher than that of patients with a STI of <60 days.²² However, if patients were further divided on the basis of the type of lung cancer, this difference was only significant in patients with NSCLC.²² However, the number of patients included in this study was only 103 (96 men).²² Two other studies, with 378 and 410 patients each, found that delaying diagnosis and treatment did not affect patient survival rates.^{16,17} Another study of 466 patients with NSCLC found that patients with shorter STIs had lower survival rates.²³ One study with 189 patients with lung cancer found that treatment delay resulted in poorer prognosis for patients,²⁴ while another study with 132 patients found that longer specialist treatment

delay does not result in poorer prognosis.²⁵ An aforementioned article also observed that most previous studies in different countries were monocentric studies and that it is difficult to decide which study is most reliable with regards to whether treatment delay affects patient survival rates.⁴

Most studies show no relationship between time-to-chemotherapy and their survival rate.²⁶ However, it should be noted that in these review articles, the number of cases collected is generally very low, with the highest number of patients only 10 583.²⁶ Another study showed time intervals from diagnosis to treatment were not associated with survival outcomes in NSCLC.²⁷ In this previous study, they discussed NSCLC patients with different treatment such as surgery, radiotherapy, systemic therapy and palliative care, which were not discussed in our study. They also suggested that delays to treatment might impact on

Table 4 Relative risk of death in patients for different treatment intervals and at different cancer stages

Variables	Stage I*				Stage II*				Stage III*				Stage IV*			
	HR	95% CI	P value†		HR	95% CI	P value†		HR	95% CI	P value†		HR	95% CI	P value†	
Interval from cancer diagnosis to treatment																
≤7 days (ref.)																
8~14 days	1.45	1.28 1.64	<0.001		1.21	1.01 1.45	0.039		1.04	0.98 1.09	0.177		0.99	0.95 1.03	0.561	
15~60 days	1.66	1.49 1.84	<0.001		1.44	1.22 1.69	<0.001		1.02	0.97 1.07	0.560		1.01	0.98 1.04	0.572	
≥61 days	2.41	2.06 2.83	<0.001		1.58	1.26 1.97	<0.001		1.13	1.06 1.21	<0.001		0.98	0.94 1.02	0.249	

*Patient age, gender, monthly salary, level of urbanisation of place of residence, CCI score, other illness, MDT care, hospital level, hospital ownership and hospital services volume were all controlled for using various models.

†Adjusted Cox proportional hazards model.

CCI, Charlson Comorbidity Index; MDT, multidisciplinary team.

Figure 1 Adjusted survival curve in lung cancer patients with different cancer stages.

other outcomes other than survival. However, there were only 1729 patients in this previous study.²⁷ In summary, the majority of previous studies into whether treatment delay affects survival rate in patients with NSCLC lack large-scale nationwide statistical data. This can easily lead to bias and produce divergent conclusions. In this study, we collected nationwide data from 42 962 patients with NSCLC which, to the best of our knowledge, is the largest nationwide study to date. In addition, we also investigated the correlation between lung cancer treatment delay and survival rate in different cancer stages (stages I, II, III and IV).

In addition, detailed examination of the literature found that a decreased treatment delay increases the risk of death in patients; the explanation provided for this is that a shorter treatment delay may mean that the patients have more obvious or more severe symptoms.²³ Therefore, there is a need to correct the result with cancer stage and severity.²³ A previous study has also suggested that a shorter treatment delay may reflect a requirement for more urgent treatment due to severity of symptoms, resulting in a poor prognosis.²⁸ Therefore, in this paper, we also considered the effects of cancer stage on treatment delay and patient prognosis. In another paper, it was also mentioned that the definition of treatment delay should be more standardised and accurate.⁴ Another paper mentioned that it is not easy to accurately calculate the time of treatment initiation.²³ In addition, the calculation of patient delay (from symptom to doctor) is also prone to errors. Therefore, in this study, our definition of treatment delay was made according to the cancer registration archives and NHI database, from pathological diagnosis confirmation until treatment initiation.

For patients with cancer in general, current medical guidelines all recommend early diagnosis and treatment to improve patient prognosis. However, early diagnosis is difficult due to multiple factors, such as non-apparent symptoms and patient delay. However, in this study, we found that if the interval from confirmation of

pathological diagnosis to treatment initiation in patients with NSCLC is shortened to 7 days, this is associated with an improvement in 5-year life expectancy (improvements of 0.49%–9.07% were observed, according to the different stages of lung cancer). We also found that this improvement in 5-year survival rate was particularly marked for patients with NSCLC at early stages (stage I and II), at 10.28%–10.34%. However, in late stage (stage III and stage IV) patients, the 5-year survival rate was only increased by 1.91% and 0.49%. It is extremely ambitious for lung cancer treatment to commence within 7 days of diagnosis considering the staging exam taking time. This group in the study (<7 days to treatment) may be skewed towards those whose cancer was diagnosed at the time or surgery. A previous study showed that NSCLC growth rate appeared to be highly variable and related to histological subtype, which was not discussed in our study.²⁹ Doubling times can be quite variable in different stages of NSCLC. Another study showed that rapid tumour progression was noted in patients with untreated, predominantly stage III NSCLC.³⁰ In our study, table 4 shows stage III NSCLC patients with the interval from diagnosis to treatment initiation more than 60 days had significantly higher relative risk of death than patients with an interval ≤ 7 days (HR 1.13, 95% CI 1.06 to 1.21). This may be due to rapid tumour progression characteristics of stage III NSCLC. However, the delay treatment effect is not significant in patients with stage IV NSCLC, which may be associated with poor outcome and low survival rate in late stage of NSCLC. Therefore, we recommended that in future policies, treatment recommendations should be formulated so that patients can start treatment within 7 days after pathological diagnosis confirmation of NSCLC to increase their 5-year survival rate. This is particularly important for patients with early stage (stage I and II) NSCLC, where improvement effects are more significant.

In this study, we also found that the effect of the interval from diagnosis to treatment initiation and patient survival rate decreased with more advanced cancer stages. Therefore, in patients who have stage I (HR 1.45–2.41) or stage II (HR 1.21–1.58) cancer, the longer the interval from diagnosis to treatment initiation, the higher the risk of death in patients. However, in stage III patients, compared with patients with an interval from diagnosis to treatment initiation ≤ 7 days, only when the interval from diagnosis to treatment initiation was ≥ 61 days was the risk of death increased. However, the magnitude of the increased risk of death is lower than in stage I and II patients (HR 1.03–1.06). It appears the association between time to treatment and outcome is stronger with lower stage disease. This may have implications on resource allocation specifically addressing the time to treatment (TTT) phenomenon. Further study, however, is necessary to better understand causation.

In recent studies, it was found that patients with oral cancers who underwent MDT treatment had significantly higher survival rates and that the proportion of patients who underwent treatment was higher than those who

did not join MDT.³¹ Previous studies have shown that the use of MDT care in cancer treatment can improve patient prognosis.³² This is particularly the case in head and neck cancers, where MDT care is cost-effective and can improve survival rates.³³ Previous studies have shown that in patients with lung cancer MDT care can significantly improve the patient's acceptance of treatment but does not significantly improve patient survival rates.³² In this study, we found that patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR 0.91, 95% CI 0.88 to 0.94).

In summary, this study identifies an association between time to treat and survival in NSCLC. Although causation is not definitive, efforts to diminish time to treat in the patient with lung cancer would seem prudent while awaiting further study on the issue. In addition, in patients with NSCLC, we recommend the addition of MDT care to decrease the risk of death and improve prognosis.

Limitations

A secondary random database derived from the NHIRD was employed for this study. The information on individual lifestyle and health behaviours, which may also affect the result, is not available. The lung function testing such as FEV₁ and DLCO is not available in our database, and disease-free survival is also not available in our study.

CONCLUSIONS

In this study, we collected nationwide data from 42962 patients with NSCLC which, to the best of our knowledge, is the largest nationwide study to date. In addition, we also investigated the correlation between lung cancer treatment delay and survival rate in different cancer stages (stages I, II, III and stage IV) with pathological confirmation. Treatment timeliness is associated with better survival rates in patients with NSCLC, particularly stages I and II.

Author affiliations

- ¹Department of Public Health, China Medical University, Taichung, Taiwan
- ²Department of Emergency Medicine, Miaoli General Hospital Ministry of Health and Welfare, Miaoli, Taiwan
- ³Department of Healthcare Administration, Asia University, Taichung, Taiwan
- ⁴Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan
- ⁵Department of Health Services Administration, China Medical University, Taichung, Taiwan

Acknowledgements We are grateful to the Science Centre of the Ministry of Health and Welfare for providing us with access to the National Health Insurance Research Database, Cancer Registry Files and Cause of Death File. We are also grateful to Health Data Science Centre, China Medical University Hospital for providing administrative, technical and funding support.

Contributors Conceptualisation: C-HT, P-TK and W-CT. Methodology: all authors. Software: W-CT. Validation: C-HT, P-TK and W-CT. Formal analysis: C-HT and W-YK. Data curation: C-HT, P-TK and W-CT. Resources: P-TK and W-CT. Writing (original draft preparation): C-HT and W-CT. Writing (review and editing): C-HT, P-TK and W-CT. Supervision: W-CT. Project administration: C-HT, W-YK and P-TK. Funding acquisition: P-TK and W-CT.

Funding This study was supported by the grants (CMU107-ASIA-18; MOST 104-2410 H-039 –002) from China Medical University, Asia University and the Ministry of Science and Technology, Taiwan.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. This study used the National Health Insurance Research Database published by the Ministry of Health, Taiwan. Due to legal restrictions imposed by the Taiwan government related to the Personal Information Protection Act, the database cannot be made publicly available. All researchers can apply for using the databases for conducting their studies. Requests for data can be sent as a formal proposal to the Science Center of the Ministry of Health and Welfare (<http://www.mohw.gov.tw/EN/Ministry/Index.aspx>). Any raw data are not allowed to be brought out from the Science Center. Only the analytic outputs in format of table or figure can be printed out. The restrictions prohibited the authors from making the minimal data set publicly available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Wen-Chen Tsai <http://orcid.org/0000-0002-9684-0789>

REFERENCES

- 1 Ferlay J, Shin H-R, Bray F, *et al*. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893–917.
- 2 Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncol* 2002;41:147–52.
- 3 Valdés S, García E, Pérez H, *et al*. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC Rev* 2010;12:29–32.
- 4 Vinas F, Ben Hassen I, Jabot L, *et al*. Delays for diagnosis and treatment of lung cancers: a systematic review. *Clin Respir J* 2016;10:267–71.
- 5 Storm HH, Dickman PW, Engeland A, *et al*. Do morphology and stage explain the inferior lung cancer survival in Denmark? *Eur Respir J* 1999;13:430–5.
- 6 Teppo L, Dickman PW, Hakulinen T, *et al*. Cancer patient survival—patterns, comparisons, trends—a population-based Cancer Registry study in Finland. *Acta Oncol* 1999;38:283–94.
- 7 Ettinger DS, Wood DE, Akerley W, *et al*. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *J Natl Compr Canc Netw* 2016;14:255–64.
- 8 Chandra S, Mohan A, Guleria R, *et al*. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10:453–6.
- 9 Chiang C-J, You S-L, Chen C-J, *et al*. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. *Jpn J Clin Oncol* 2015;45:291–6.
- 10 Cheng C-L, Kao Y-HY, Lin S-J, *et al*. Validation of the National health insurance research database with ischemic stroke cases in Taiwan. *Pharmacoepidemiol Drug Saf* 2011;20:236–42.
- 11 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613–9.
- 12 Bilimoria KY, Ko CY, Tomlinson JS, *et al*. Wait times for cancer surgery in the United States: trends and predictors of delays. *Ann Surg* 2011;253:779–85.
- 13 Evans SM, Earnest A, Bower W, *et al*. Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Med J Aust* 2016;204:75.
- 14 Gomez DR, Liao K-P, Swisher SG, *et al*. Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival. *Radiother Oncol* 2015;115:257–63.
- 15 Liberman M, Liberman D, Sampalis JS, *et al*. Delays to surgery in non-small-cell lung cancer. *Can J Surg* 2006;49:31.
- 16 Pita-Fernández S, Montero-Martínez C, Pértiga-Díaz S, *et al*. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. *J Clin Epidemiol* 2003;56:820–5.

- 17 Porta M, Gallén M, Malats N, *et al.* Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites. *J Epidemiol Community Health* 1991;45:225–30.
- 18 Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. *Lung Cancer* 2002;35:53–7.
- 19 Billing JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax* 1996;51:903–6.
- 20 Mor V, Masterson-Allen S, Goldberg R, *et al.* Pre-Diagnostic symptom recognition and help seeking among cancer patients. *J Community Health* 1990;15:253–66.
- 21 Christensen ED, Harvald T, Jendresen M, *et al.* The impact of delayed diagnosis of lung cancer on the stage at the time of operation. *Eur J Cardiothorac Surg* 1997;12:880–4.
- 22 Annakkaya AN, Arbak P, Balbay O, *et al.* Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori* 2007;93:61–7.
- 23 Myrdal G, Lambe M, Hillerdal G, *et al.* Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax* 2004;59:45–9.
- 24 Robinson E, Mohilever J, Zidan J, *et al.* Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. *Cancer* 1984;54:1454–60.
- 25 Salomaa E-R, Sällinen S, Hiekkanen H, *et al.* Delays in the diagnosis and treatment of lung cancer. *Chest* 2005;128:2282–8.
- 26 Alexander M, Blum R, Burbury K, *et al.* Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice. *Intern Med J* 2017;47:16–34.
- 27 Vinod SK, Chandra A, Berthelsen A, *et al.* Does timeliness of care in non-small cell lung cancer impact on survival? *Lung Cancer* 2017;112:16–24.
- 28 Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. *J Thorac Oncol* 2011;6:1254–9.
- 29 Mackintosh JA, Marshall HM, Yang IA, *et al.* A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. *Respirology* 2014;19:755–62.
- 30 Everitt S, Herschtal A, Callahan J, *et al.* High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. *Cancer* 2010;116:5030–7.
- 31 Tsai W-C, Kung P-T, Wang S-T, *et al.* Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: results of a nationwide cohort study in Taiwan. *Oral Oncol* 2015;51:105–11.
- 32 Boxer MM, Vinod SK, Shafiq J, *et al.* Do multidisciplinary team meetings make a difference in the management of lung cancer? *Cancer* 2011;117:5112–20.
- 33 Birchall M, Bailey D, King P, *et al.* Effect of process standards on survival of patients with head and neck cancer in the South and West of England. *Br J Cancer* 2004;91:1477–81.